COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer

Protocol No
IIT-ERICKSON-RT-PANCREAS
Principal Investigator
Beth Erickson
Phase
II
Summary
In this study we want to find out more about the efficacy of giving higher doses of radiation with concurrent chemotherapy in controlling unresectable pancreas cancers than are used in either the pre-operative or post-operative setting. We also want to assess the acute and late side effects (problems and symptoms) of radiation therapy given at these higher doses of radiation (dose escalated) following full dose chemotherapy given before the radiation and with concurrent chemotherapy for pancreas cancer. Radiation therapy is given in higher doses that are limited by the proximity of your normal organs to the radiation dose distribution to improve the likelihood of controlling the tumor in the pancreas while minimizing the risk of radiation injury to these organs. There are two chemotherapy drugs, Capecitabine is an oral drug taken twice per day on the same day that radiation therapy is given and Gemcitabine is an intravenous drug given once per week. Everyone in this study will have already received chemotherapy alone first. Everyone in this study will receive radiation therapy and concurrent chemotherapy. We do not know how well this treatment may affect your pancreas cancer.
Description
MR Guided Dose Escalated RT + Concurrent Chemotherapy in Unresectable Pancreatic Cancer
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL